InvestSMART

Acrux Limited (ASX: ACR) - Announcements

- Current share price for ACR : $0.010

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Suspension and request 16 Jul 2007 9:27AM $1.720 $0.010 fallen by 99.42%
$6 Positive results in Phase 2 trial of Testosterone MD-Lotion 16 Jul 2007 9:15AM $1.720 $0.010 fallen by 99.42%
$6 Trading halt 12 Jul 2007 9:11AM $1.720 $0.010 fallen by 99.42%
$6 Positive Trial Results - Combination Contraceptive Sprays 3 Jul 2007 10:17AM $1.650 $0.010 fallen by 99.39%
$6 Estradiol spray to be marketed in Australia by Aspen 21 Jun 2007 8:58AM $1.570 $0.010 fallen by 99.36%
$6 EvaMist sublicense from Vivus to KV Pharmaceutical completed 17 May 2007 5:25PM $1.240 $0.010 fallen by 99.19%
$6 Commitments Test Entity - Third Quarter Report 30 Apr 2007 4:22PM $1.315 $0.010 fallen by 99.24%
$6 Vivus to sub-license EvaMist rights to KV Pharmaceutical 2 Apr 2007 11:01AM $1.420 $0.010 fallen by 99.30%
$6 Second commercial agreement with Organon 7 Mar 2007 8:36AM $1.250 $0.010 fallen by 99.20%
$6 To develop contraceptive sprays 1 Mar 2007 8:45AM $1.200 $0.010 fallen by 99.17%
$6 Half Yearly Report & Half Year Accounts 14 Feb 2007 12:53PM $1.070 $0.010 fallen by 99.07%
$6 Response to ASX Query 12 Feb 2007 9:55AM $1.010 $0.010 fallen by 99.01%
$6 Commitments Test Entity - Second Quarter Report 31 Jan 2007 4:04PM $1.050 $0.010 fallen by 99.05%
$6 FDA Acceptance for review of drug application for Evamist 13 Dec 2006 10:29AM $0.780 $0.010 fallen by 98.72%
$6 Commitments Test Entity - First Quarter Report 31 Oct 2006 9:34AM $0.750 $0.010 fallen by 98.67%
$6 Expands animal health partnership with Eli Lilly & Company 31 Oct 2006 8:52AM $0.750 $0.010 fallen by 98.67%
$6 Acrux US licensee submits NDA for EvaMist to FDA 3 Oct 2006 10:03AM $0.840 $0.010 fallen by 98.81%
$6 To start USA Trial of Unique Testosterone Lotion for Men 18 Sep 2006 11:46AM $0.710 $0.010 fallen by 98.59%
$6 Preliminary Final Report & Full Year Accounts 31 Aug 2006 9:37AM $0.770 $0.010 fallen by 98.70%
$6 Broadens contraceptive spray strategy 10 Aug 2006 9:25AM $0.845 $0.010 fallen by 98.82%
$6 Secures TGA Licence to Manufacture Clinical Trial Supplies 9 Aug 2006 12:59PM $0.820 $0.010 fallen by 98.78%
$6 Commitments Test Entity - Fourth Quarter Report 31 Jul 2006 5:30PM $0.840 $0.010 fallen by 98.81%
$6 Shareholder Update - July 2006 26 Jul 2006 9:30AM n/a $0.010 n/a
$6 Positive results for Acrux lead product in US Phase 3 trial 8 May 2006 8:50AM $0.820 $0.010 fallen by 98.78%
$6 Trading Halt 5 May 2006 9:29AM n/a $0.010 n/a

651 - 675 of 696 results

Page 27 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.